{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/menopause/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"ddcba55c-566e-5433-8dce-2e5f5cee0ba4","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field b18d5b2b-4d1b-4d05-9e0f-4d93fcdff67f --><h2>Changes</h2><!-- end field b18d5b2b-4d1b-4d05-9e0f-4d93fcdff67f -->","summary":null,"htmlStringContent":"<!-- begin item 7c6051ef-e565-4b69-a940-7fa7f55b9581 --><!-- begin field 81a5cbbc-13fa-4865-9f19-fe5776cf8c27 --><p><strong>October to November 2020</strong> — reviewed. A literature search was conducted in August 2020 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. The topic has undergone minor restructuring to improve clarity and navigation. The lowest age-range of the topic has been changed from 40 to 35 years, to include the diagnosis and management of suspected premature ovarian insufficiency (POI). The recommendations have been updated in line with the National Institute for Health and Care Excellence (NICE) clinical guideline Menopause [NICE, 2019] and other relevant literature. Additional options for non-hormonal therapy include the use of paroxetine, clonidine, gabapentin, or cognitive behavioural therapy (CBT) for the management of vasomotor symptoms. Additional information for women with hypothyroidism has been added to the section on Managing co-morbidities. A new node on Referral has been added to the topic, to improve clarity and navigation.</p><!-- end field 81a5cbbc-13fa-4865-9f19-fe5776cf8c27 --><!-- end item 7c6051ef-e565-4b69-a940-7fa7f55b9581 -->","topic":{"id":"69003588-b736-585d-8a5d-7ca0e916caa5","topicId":"f75fa6a7-10c6-4887-9cf1-3ea14d7f353c","topicName":"Menopause","slug":"menopause","lastRevised":"Last revised in November 2020","chapters":[{"id":"0359e5fa-1342-5767-a4da-2f8b5cd2b6db","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"c978ff88-dda8-5879-a0ac-9b09182d81d1","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"d381eed9-6611-5263-a3be-b46ec9f02058","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"ddcba55c-566e-5433-8dce-2e5f5cee0ba4","slug":"changes","fullItemName":"Changes"},{"id":"e521b2f5-34d4-580f-b63d-a1ec2d0c13a3","slug":"update","fullItemName":"Update"}]},{"id":"ab5690cf-81b4-5fa9-b69f-27abc2e034a3","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"c0f45ff8-442c-5027-922e-12d108200960","slug":"goals","fullItemName":"Goals"},{"id":"8459ae09-bdf2-5d0d-9728-538e93d05a8f","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"43027e52-84ef-53fa-88c5-a84289154e48","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"4620ee3c-97ae-5f9f-8bac-fc8497801cdb","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"b26fb3cf-562a-595a-8f9e-92fd752d2e6b","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"10c1cb80-22cc-5889-8e30-35cf1a9843bf","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"18c173af-ec8a-571c-be49-d894f0bec50b","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"8e86f5f5-2343-5ea3-8d0d-7dda791a066e","slug":"definition","fullItemName":"Definition"},{"id":"17295b39-3f33-5e75-8d8a-1fc32c2efb70","slug":"causes","fullItemName":"Causes"},{"id":"5b768dab-f7db-50c3-8686-0d363f36e74d","slug":"prevalence","fullItemName":"Prevalence"},{"id":"698848d3-f122-5e5a-acc8-98518854f51b","slug":"complications","fullItemName":"Complications"},{"id":"647a928d-775d-5b0b-b577-b695140b26a3","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"00aeafb7-f9e4-5fd2-8fd2-57bd7fd333d8","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"d68ce2dd-2971-5c66-b22c-df0db848cf06","slug":"diagnosis-of-menopause-perimenopause","fullItemName":"Diagnosis of menopause and perimenopause"},{"id":"8b9c8208-91c2-5751-8a76-dc9461736050","slug":"diagnosis-of-premature-ovarian-insufficiency","fullItemName":"Diagnosis of premature ovarian insufficiency"},{"id":"a84016e1-b7af-55f9-b1f8-c85ff76cfc93","slug":"assessment","fullItemName":"Assessment"},{"id":"6c51a87c-f89c-5e58-b495-39506bc70e62","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"649507f8-7b95-5740-9833-fee7c5bff092","fullItemName":"Management","slug":"management","subChapters":[{"id":"9c13d541-f2ee-5d0a-a174-cd7c7b4aa392","slug":"management-of-menopause-perimenopause-or-premature-ovarian-insufficiency","fullItemName":"Scenario: Management of menopause, perimenopause, or premature ovarian insufficiency"}]},{"id":"7d937659-3134-52f9-8742-b90a6ffb1f1f","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"19b6008a-dd02-5fdb-b146-5cb427bb1f29","slug":"hormone-replacement-therapy-hrt","fullItemName":"Hormone replacement therapy (HRT)"}]},{"id":"ff6b5c36-2033-50a7-9c74-c9e46f1c8242","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"c9280136-8c1b-5890-96e2-c8f14078bb5f","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"4f9c2c0d-8ea0-5048-8ae4-0b2517bed5ca","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"4b187b70-dcd7-5e05-ac85-fd75204e2515","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"b3e44a7a-44e1-5dec-bd9e-67a0cad5baca","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"6e1b4175-c43f-53ce-8884-b9f1b5b39f58","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"6e0d3a8f-c4c1-533c-b265-34d08681175b","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"e6340cdd-13d8-5fde-912f-a3d2c50f305f","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"d381eed9-6611-5263-a3be-b46ec9f02058","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"c60c38ac-62b1-50cc-b41a-6efc8ec7e677","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field e0195f60-68a7-4dda-bb48-f1d7512753c3 --><h3>Previous changes</h3><!-- end field e0195f60-68a7-4dda-bb48-f1d7512753c3 -->","summary":null,"htmlStringContent":"<!-- begin item fe420e51-24a9-4351-89a3-b496cffa24a1 --><!-- begin field 7d6d2dac-798b-4ac1-9069-80b6bf1f53fa --><p><strong>April 2020</strong> — minor update. Minor typographical error corrected.</p><p><strong>March 2017</strong> — minor update. More information on results of the Collaborative Group on Epidemiological Studies of Ovarian Cancer has been included in the topic, and a link to the meta-analysis has been included [Collaborative group on epidemiological studies of ovarian cancer, 2015].</p><p><strong>December 2016</strong> — minor update.</p><ul><li>Information that a combined oestrogen/bazedoxifene acetate product (Duavive®) is available for postmenopausal women with a uterus (with at least 12 months since the last menses) for whom progestogen-containing therapy is not appropriate, has been added to this topic [ABPI, 2016]. Minor text change on the effectiveness of gabapentin for reducing hot flushes has also been added. </li><li>Information on the risk of ovarian cancer associated with hormone replacement therapy (HRT) has been clarified, in line with the manufacturers' updated Summary of Product Characteristics [ABPI, 2016].</li><li>The adverse effects of HRT have been updated to include angioedema, and advice that people requiring thyroid replacement therapy should have their thyroid function monitored regularly while taking HRT has been added [ABPI, 2016].</li></ul><p><strong>November 2016 </strong>— minor update. Information on testosterone removed from the section on management without HRT.</p><p><strong>October 2015</strong> — reviewed. A literature search was conducted in October 2015 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. The recommendations have been updated in line with recommendations in the National Institute for Health and Care Excellence (NICE) draft guideline <em>Menopause</em> [National Collaborating Centre for Women, 2015]. The topic has also been restructured.</p><p><strong>February 2015 </strong>— minor update. Testosterone implants have been discontinued. References to testosterone implants have been removed from the topic.</p><p><strong>December 2014 </strong>— minor update. The recommendations for managing women with current or previous breast cancer have been re-written for the purposes of improved clarity.</p><p><strong>July 2014 </strong>— minor update. Update to the text on the use of unopposed oestrogen in women with an intact uterus. The manufacturers of Evorel<sup>® </sup>advise that if oestrogens are administered alone for prolonged periods, the risk of endometrial cancer may remain elevated for at least 10 years, even after stopping treatment.</p><p><strong>March 2014 </strong>— minor update. Text amended to clarify the recommendations on how to stop cyclical combined HRT patches and continuous combined HRT patches.</p><p><strong>May to June 2013 </strong>— reviewed. A literature search was conducted in April 2013 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of the topic. No major changes to clinical recommendations have been made. However, the evidence summary on risks associated with the use of hormone replacement therapy has been updated in line with two recent Cochrane systematic reviews.</p><p><strong>February 2012</strong> — minor update. Estraderm TTS 25<sup>® </sup>and Estraderm TTS 100<sup>® </sup>patches have been discontinued. The prescriptions for these products have been removed. Issued in March 2012.</p><p><strong>January 2012</strong> — minor update. Added updated information from the manufacturer's Summary of Product Characteristics (SPC) stating that venlafaxine may alter glycaemic control in people with diabetes mellitus. Issued in January 2012.</p><p><strong>January 2012</strong> — minor update. Lundbeck Ltd in collaboration with the Medicines and Healthcare products Regulatory Agency (MHRA), has published new safety data regarding the association of citalopram and escitalopram with dose-dependent QT interval prolongation. This topic has been updated to reflect their advice. Issued in January 2012.</p><p><strong>May 2011</strong>— interaction between SSRIs and tamoxifen added as stated in the most recent Summaries of Product Characteristics (SPCs). </p><p><strong>April 2011 </strong>— topic structure revised to ensure consistency across CKS topics. No changes to clinical recommendations have been made.</p><p><strong>April 2011</strong>— minor update. A prescription for estriol 0.01% vaginal cream (Gynest<sup>®</sup>) has been added. Issued in June 2011.</p><p><strong>March 2011 </strong>— topic structure revised to ensure consistency across CKS topics. No changes to clinical recommendations have been made.</p><p><strong>December 2010 </strong>— minor update. Premique<sup>® </sup>cycle tablets and Premarin<sup>® </sup>vaginal cream have been discontinued. The prescriptions have been removed. Issued in December 2010.</p><p><strong>July 2010 </strong>— minor update. Harmogen tablets (estropipate 1.5 mg) have been discontinued. The prescriptions for this product have been removed. Issued in July 2010.</p><p><strong>April 2009 </strong>— minor update. Estraderm TTS50<sup>® </sup>patches and EstraCombi<sup>® </sup>patches are being discontinued during May to July 2009. The prescriptions for these products have been removed. Estraderm TTS25<sup>® </sup>and Estraderm TTS100<sup>® </sup>patches will continue to be available. Issued in May 2009.</p><p><strong>March 2009 </strong>— minor update to the evidence section for antidepressants. Text discussing a sensitivity analysis for antidepressants is now included. Issued in March 2009.</p><p><strong>February 2009 </strong>— advice from the Medicines and Healthcare products Regulatory Agency (MHRA) that tibolone increases the risk of breast cancer recurrence in women with a history of breast cancer has been included. Issued March 2009.</p><p><strong>September 2008</strong>—minor correction to <em>Changes </em>section. Issued in September 2008.</p><p><strong>March 2008 </strong>— minor text update to the basis of the recommendation about possible risks of HRT.</p><p><strong>October 2007 to January 2008 </strong>— converted from CKS guidance to CKS topic structure. The evidence-base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence.</p><p><strong>July 2006 </strong>— minor update. The Commission on Human Medicines' (CHM) update on the risk of endometrial cancer with HRT and tibolone has been included. Evorel Pak<sup>® </sup>discontinued and prescriptions removed. Issued in July 2006.</p><p><strong>April 2006 </strong>— minor update. Estradiol 100 mg implant discontinued and prescriptions removed. Issued in May 2006.</p><p><strong>October 2005 </strong>— minor technical update. Issued in November 2005.</p><p><strong>July 2005 </strong>— updated to incorporate the <em>Referral guidelines for suspected cancer </em>published by the National Institute for Health and Clinical Excellence. Issued in July 2005.</p><p><strong>February 2005 </strong>— correction to table in line with <em>Long-term benefits of HRT: results from the Women's Health Initiative study</em>. Issued in February 2005.</p><p><strong>November 2004 </strong>— updated to include the latest review of the evidence on long-term safety of HRT from the Committee on Safety of Medicines (CSM). Issued in November 2004.</p><p><strong>March 2004 </strong>— reviewed. Validated in May 2004 and issued in July 2004.</p><p><strong>June 2001 </strong>— rewritten. Validated in July 2001 and issued in October 2001.</p><p><strong>April 1998 </strong>— reviewed.</p><p><strong>September 1997 </strong>— written.</p><!-- end field 7d6d2dac-798b-4ac1-9069-80b6bf1f53fa --><!-- end item fe420e51-24a9-4351-89a3-b496cffa24a1 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}